Fig. 4
From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Cost-effectiveness acceptability curve. These probability that a specific treatment is cost-effective at a given Willingness-to-pay threshold of NT 2,213,145 (=US$ 67065, 1 US = 33 NT). SBRT, stereotactic body radiotherapy